MPM BioImpact LLC 13F Portfolio

CIK 1687078 Filing since Q4 2019 Q3 2026 filed Nov 16, 2026
Holdings as of Sep 30, 2026, from the 13F filed Nov 16, 2026.

Portfolio Snapshot

36 positions · Q3 2026

MPM BioImpact LLC reported 36 positions worth $1.30B for the quarter ended Sep 30, 2026, down 19.8% on the prior quarter. It opened 9 new positions, added to 8, trimmed 18 and exited 9. Its largest holding is Cullinan Therapeutics, Inc. at 11.5% of the portfolio.

Portfolio Value
$1.30B
-19.8% QoQ · +129.4% YoY
Positions
36
9 new · 9 sold out
Top 10 Concentration
49.3%
of portfolio value
Largest Position
CGEM 11.5%
Cullinan Therapeutics, Inc.
Net Buying
-$64.37M
$304.79M bought · $369.16M sold
Turnover
20.9%
of the portfolio traded
Top Sector
Healthcare
100% of value
Track Record
28
quarters on file since Q4 2019

Portfolio Value & Positions

Value Positions

Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.

Sector Allocation

1 sectors
100%
Healthcare
Healthcare100%

Quarterly Buying & Selling

Bought Sold

Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.

Position Changes

How many positions were opened, added to, trimmed or closed each quarter.

Sector Allocation Over Time

Share of reported value in each sector at every quarter end.

HealthcareOther

Largest Buys

Q3 2026
Holding Change Change % Trade Value Weight
IOVA Iovance Biotherapeutics, Inc. +2.84M – $42.03M 3.24%
IMCR Immunocore Holdings plc +1.20M – $36.45M 2.81%
VIR Vir Biotechnology, Inc. +2.81M – $31.41M 2.42%
VSTM Verastem, Inc. +3.85M – $31.01M 2.39%
ODTX Odyssey Therapeutics, Inc. +1.29M – $28.64M 2.2%
ORKA Oruka Therapeutics, Inc. +300.0K – $24.99M 1.92%
ACRS Aclaris Therapeutics, Inc. +4.14M +396.7% $21.75M 2.1%
NGNE Neurogene Inc. +771.8K – $21.47M 1.65%
DYN Dyne Therapeutics, Inc. +1.29M +66.9% $20.72M 3.98%
TSHA Taysha Gene Therapies, Inc. +2.76M +61.4% $13.46M 2.72%

Largest Sells

Q3 2026
Holding Change Change % Trade Value Weight
RVMD Revolution Medicines, Inc. -492.5K -100.0% $92.23M Exited
ALMS Alumis Inc. -2.02M -100.0% $56.82M Exited
RARE Ultragenyx Pharmaceutical Inc. -1.42M -100.0% $47.35M Exited
DNTH Dianthus Therapeutics, Inc. -420.0K -100.0% $40.94M Exited
CORT Corcept Therapeutics Inc -349.0K -45.3% $40.22M 3.74%
MLTX MoonLake Immunotherapeutics -1.61M -100.0% $31.29M Exited
SNDX Syndax Pharmaceuticals Inc -1.33M -100.0% $29.15M Exited
TRDA Entrada Therapeutics, Inc. -1.25M -100.0% $9.22M Exited
DBVT DBV Technologies S.A. -621.6K -17.0% $7.31M 2.76%
TVTX Travere Therapeutics, Inc. -34.4K -3.1% $2.02M 4.93%

New Positions

Q3 2026
Holding Shares Trade Value Weight
IOVA Iovance Biotherapeutics, Inc. +2.84M $42.03M 3.24%
IMCR Immunocore Holdings plc +1.20M $36.45M 2.81%
VIR Vir Biotechnology, Inc. +2.81M $31.41M 2.42%
VSTM Verastem, Inc. +3.85M $31.01M 2.39%
ODTX Odyssey Therapeutics, Inc. +1.29M $28.64M 2.2%
ORKA Oruka Therapeutics, Inc. +300.0K $24.99M 1.92%
NGNE Neurogene Inc. +771.8K $21.47M 1.65%
CRBP Corbus Pharmaceuticals Holdings, Inc. +1.67M $11.37M 0.875%
TRAX First Tracks Biotherapeutics, Inc. +254.4K $9.02M 0.694%

Closed Positions

Q3 2026
Holding Shares Sold Trade Value Prior Weight
RVMD Revolution Medicines, Inc. -492.5K $92.23M 5.7%
ALMS Alumis Inc. -2.02M $56.82M 3.51%
RARE Ultragenyx Pharmaceutical Inc. -1.42M $47.35M 2.92%
DNTH Dianthus Therapeutics, Inc. -420.0K $40.94M 2.53%
MLTX MoonLake Immunotherapeutics -1.61M $31.29M 1.93%
SNDX Syndax Pharmaceuticals Inc -1.33M $29.15M 1.8%
TRDA Entrada Therapeutics, Inc. -1.25M $9.22M 0.57%
CNTX Context Therapeutics Inc. -1.30M $719.54K 0.044%
HOWL Werewolf Therapeutics, Inc. -80.1K $28.85K <0.01%
Holdings · Q3 2026

36 Positions

As ofSep 30, 2026
Value$1.30B
Top 1049.3%
Avg position$36.09M
# Activity
21 more holdings Create a free account to keep reading this institution’s full portfolio.
Showing 1–15 of 36 positions 13F filings on SEC EDGAR

Tip. Select a row to see that position’s full history at MPM BioImpact.

About MPM BioImpact LLC’s 13F Portfolio

What are MPM BioImpact LLC’s largest holdings?

As of its Q3 2026 13F filing, MPM BioImpact LLC’s five largest positions were Cullinan Therapeutics, Inc. (CGEM) at 11.5%, Aktis Oncology, Inc. (AKTS) at 7.2%, Travere Therapeutics, Inc. (TVTX) at 4.9%, Edgewise Therapeutics, Inc. (EWTX) at 4.9%, Dyne Therapeutics, Inc. (DYN) at 4.0% of the reported portfolio.

How much is MPM BioImpact LLC’s portfolio worth?

MPM BioImpact LLC reported a 13F portfolio worth $1.30B across 36 positions for Q3 2026. That is down 19.8% from the previous quarter.

What did MPM BioImpact LLC buy in Q3 2026?

Its largest purchases by value were Iovance Biotherapeutics, Inc. ($42.03M), Immunocore Holdings plc ($36.45M), Vir Biotechnology, Inc. ($31.41M). It opened 9 new positions.

What did MPM BioImpact LLC sell in Q3 2026?

Its largest sales by value were Revolution Medicines, Inc. ($92.23M), Alumis Inc. ($56.82M), Ultragenyx Pharmaceutical Inc. ($47.35M). It exited 9 positions entirely.

Where does this data come from?

From the Form 13F-HR reports MPM BioImpact LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.

Similar-Sized Institutions

by reported 13F value

13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.